ClinicalTrials.Veeva

Menu
O

Options Research Group | West Lafayette, Indiana

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Upadacitinib
Rocatinlimab
IMG-007
ALD-102
Omalizumab
AMG 451
Dupilumab
etrasimod
Difamilast

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of ALD-102 Solution in Subjects With Alopecia Areata

The goal of this first-in-human clinical trial is to learn if ALD-102 Solution is safe and well tolerated following injections in the scalp in subjec...

Enrolling
Alopecia Areata (AA)
Drug: ALD-102
Drug: Placebo

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib Dose B
Drug: Upadacitinib Dose A

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo

The purpose of this study is to determine the efficacy and safety of a monoclonal antibody, OpSCF, in the treatment of adults with moderate to severe...

Active, not recruiting
Atopic Dermatitis
Biological: Placebo
Biological: OpSCF

Trial sponsors

AbbVie logo
Amgen logo
Acrotech Biopharma logo
I
K
O
Pfizer logo
A

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems